Home > SANTE - SCIENCES DE LA VIE > Industrie Pharmaceutique > Maladies Infectieuses > Stakeholder Perspectives: ...
AUTRES RESSOURCES
 
AUTRES SECTEURS
 
TOUS NOS SECTEURS
 
Maladies Infectieuses > Etude de marché sectorielle
 Stakeholder Perspectives: Influenza Vaccines - Flying back Into Flu
€ 6 460,00
Editeur :
Datamonitor
Langue :
Anglais
Date de publication :
Décembre 2005
Taille du document :
166
Autres informations :
Description , Table des matières
 

Recevez cette publication aujourd'hui !
Plus d'information ?
+33 437 37 1637
 
Documents Publics
1,200,000 documents
Téléchargement illimités
 
Etudes Privées
50,000 rapports et études
Paiement à la piéce
 
1.Télécharger nos rapports publics

Accés complet à plus de 1,2 Million de documents publics : études de marché, statistiques sectorielles, fiches pays, monographie d'entreprises, veille concurentielle, rapports annuels...

Nos documents publics sur le même théme (1)
Infectious diseases market in USA
58 pages | Juin 2005 | Anglais
 
 
   
Main focus: vaccine,influenza vaccine,vaccines,hepatitis b,...,...
Research focus: market outlook,market segmentation,
Geographic focus: usa,hong kong
   
Autres recherches sur le même thème
Rechercher d'autres rapports publics à télécharger
 
 
 
2. Rechercher d'autres rapports et études à commander

Rechercher et commander ici parmi 50.000 études de marché publiées par les principaux instituts d'études internationaux


Rapports privés en relation
The Antivirals Market Outlook: Market analysis of future growth and leading players by sector
178 pages | Janvier 2005 |
Business Insights have teamed up with IMS Health to bring you, ‘The Antivirals Market Outlook: Market analysis of future growth and leading players by sector.’ This unique product offering provides an
2 443,75 €
 
 
Approved AIDS and AIDS-Related Drugs, 1987-2003
1 pages | Janvier 2006 |
This Database Table is a one-page table of hard-to-find numerical information.
The Database Table is derived from a proprietary source and is meant to simply provide a high-level overview of specif
80,00 €
 
 
Pipeline Insight: Hepatitis B - New Kids on the Block
211 pages | Avril 2005 |
IntroductionAccording to the WHO, 350-400 million people are chronically infected with HBV progresses to liver cirrhosis and hepatocellular carcinoma.
Previously HBV has been treated with lamivudin
9 120,00 €
 
 
04-013: Overview of Autoimmune Disease Research
162 pages | Juin 2004 |
This overview will help life science suppliers identify opportunities to expand the placement of their immunological tools and technologies as well as assist in stimulating new product ideas and/or en
800,00 €
 
 
Lower Detection Limits of HBV DNA Assays
1 pages | Janvier 2006 |
This Database Table is a one-page table of hard-to-find numerical information.
The Database Table is derived from a proprietary source and is meant to simply provide a high-level overview of specif
80,00 €
 
 
Recommendations for Diagnostic Testing for Hepatitis B
1 pages | Janvier 2006 |
This Database Table is a one-page table of hard-to-find numerical information.
The Database Table is derived from a proprietary source and is meant to simply provide a high-level overview of specif
80,00 €
 
 
Commercial Perspectives: HIV - Benchmarking Rapid Antiretroviral Uptake
181 pages | Février 2005 |
IntroductionHistorically, HIV antiretrovirals have differed markedly in their speed of market uptake.
Now, to win market share in an already mature market, newly launched products need not only a s
9 120,00 €
 
 
Stakeholder Insight: Hepatitis B & C - Winning Battles But Not The War
329 pages | Décembre 2004 |
IntroductionAccording to the WHO, 350400 million are chronically infected with HBV and 170200 million with HCV.
Although HBV vaccination and routine screening of donated blood has decreased inciden
12 160,00 €
 
 
Chinese Markets for Vaccine
269 pages | Mars 2003 |
China's demand for vaccine has grown at a fast pace in the past decade.
In the next five years, both production and demand will continue to grow.
This new study examines China's economic trends,
2 835,00 €
 
 
Monoclonal Antibody Therapies: Evolving into a $30 billion market
360 pages | Avril 2005 |
IntroductionThe monoclonal antibody market is one of the fastest growing and most lucrative sectors of the pharmaceutical industry, with exceptional 48.1% growth between 2003 and 2004.
It has the p
12 160,00 €
 
 
 
Autres secteurs en relation
Rechercher d'autres rapports!
 
 
 
Présentation de l'étude de marché - Description & Table des matières
 Stakeholder Perspectives: Influenza Vaccines - Flying back Into Flu

Introduction
Influenza is a highly infectious disease which globally infects 10-20% of the population every year causing up to 500,000 deaths. Although all persons are at risk, the elderly and the young are the most vulnerable. For decades, trivalent prophylactic vaccines produced in chicken eggs have been used to reduce the burden of influenza with approximately 300 million doses produced globally.

Scope
Evaluation of total 2004 global vaccine market value, historical growth since 1999 and major company market share
Overview of major influenza vaccine products, producers and new product development
Expert led discussion of drivers and resistors to cell culture flu systems in seasonal/pandemic scenarios
Forecast value and demand (doses) for influenza vaccines in 2010 with launch predictions
Highlights
Despite the Chiron debacle, collective sales of influenza vaccines from Western producers surpassed the $1 billion level in 2004 with 10% growth over the previous year. Expanding recommendations for vaccination continue to fuel global demand.

Datamonitor forecasts that in the seven major markets demand for influenza vaccines will expand to 370 million doses and a market value of $3.7 billion by 2010. Global capacity will expand appropriately to meet this goal but competition will intensify with 11 predicted new product launches.

Cell culture flu could amount to 15% of US doses supplied in 2010 if the FDA can overcome safety concerns with the MDCK line. Although heralded as a much needed solution, cell culture flu still requires substantial capital investment.

Reasons to Purchase
Review an up to date expert discussion of major dynamics within the global vaccine market
Gain insight into how the market for influenza vaccines is now an attractive growth option
Understand commercial drivers and resistors for cell culture flu systems


 

Introduction
Many prescribers rely on websites provided by pharmaceutical companies when searching for treatment information. Consumers also rely heavily on online resources when searching for disease and treatment information. Websites that tailor their site content to address the specific needs of their target audience will experience greater retention of site visitors.

Reasons to Purchase
Assess and compare the value of leading global pharmaceutical companies' online presence across a number of criteria

Identify which tools and services are being used to encourage consumers and healthcare professionals to frequently revisit a website

Compare the websites of products in the same class to see what gives the leaders a competitive edge


New Search:

PPLSEN